Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H20N2O3S.ClH |
Molecular Weight | 320.835 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC
InChI
InChIKey=GDWDBGSWGNEMGJ-UHFFFAOYSA-N
InChI=1S/C13H20N2O3S.ClH/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4;/h7,9,14H,5-6H2,1-4H3,(H,15,16);1H
Articaine is a dental local anesthetic, which is the most widely used in a number of European countries and is available in many countries around the world. Articaine in combination with epinephrine under the brand name Septocaine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rising of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Articaine blocks the actions on Na+ channels. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19418088 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SEPTOCAINE Approved UseArticaine HCl and Epinephrine, an amide local anesthetic containing a vasoconstrictor, is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Articaine HCl and Epinephrine, an amide local anesthetic containing a vasoconstrictor, is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Launch Date2000 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.3 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9055188 |
600 mg 1 times / day steady-state, epidural dose: 600 mg route of administration: Epidural experiment type: STEADY-STATE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2037 ng/mL |
476 mg single, intraoral submucosal injection dose: 476 mg route of administration: Intraoral Submucosal Injection experiment type: SINGLE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
385 ng/mL |
68 mg single, dental dose: 68 mg route of administration: Dental experiment type: SINGLE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
900 ng/mL |
204 mg single, dental dose: 204 mg route of administration: Dental experiment type: SINGLE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.1 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9055188 |
600 mg 1 times / day steady-state, epidural dose: 600 mg route of administration: Epidural experiment type: STEADY-STATE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9055188 |
600 mg 1 times / day steady-state, epidural dose: 600 mg route of administration: Epidural experiment type: STEADY-STATE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
43.8 min |
476 mg single, intraoral submucosal injection dose: 476 mg route of administration: Intraoral Submucosal Injection experiment type: SINGLE co-administered: EPINEPHRINE |
ARTICAINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
ARTICAINE serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
7 mg/kg 1 times / day single, supraperiosteal injection Recommended Dose: 7 mg/kg, 1 times / day Route: supraperiosteal injection Route: single Dose: 7 mg/kg, 1 times / day Sources: Page: 96001.02 |
unhealthy, 33.7 n = 159 Health Status: unhealthy Condition: pain Age Group: 33.7 Sex: M+F Population Size: 159 Sources: Page: 96001.02 |
Sources: Page: 96001.02 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19418088/ Page: - |
yes [IC50 8.8 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7924890/ Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201751Orig1s000lbl.pdf#page=2 Page: 2.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16938156/ Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiovascular Parameters during Submaximal Exercise following Submucous Administration of Articaine : A Comparison with Lidocaine and Placebo in Young Healthy Volunteers. | 2003 |
|
[Local anesthesia failure problems in conservative dental therapy clinic]. | 2006 |
|
Local anesthetics: dentistry's most important drugs, clinical update 2006. | 2006 Dec |
|
Is permanent maxillary tooth removal without palatal injection possible? | 2006 Dec |
|
Selection of local anesthetics in dentistry: clinical impression versus scientific assessment. | 2006 Fall |
|
The ethics of adopting a new drug: articaine as an example. | 2006 Fall |
|
Articaine and paresthesia: epidemiological studies. | 2006 Fall |
|
The anesthetic efficacy of 4 percent articaine 1:200,000 epinephrine: two controlled clinical trials. | 2006 Nov |
|
The pharmacokinetics and cardiovascular effects of high-dose articaine with 1:100,000 and 1:200,000 epinephrine. | 2006 Nov |
|
Permanent nerve damage from inferior alveolar nerve blocks--an update to include articaine. | 2007 Apr |
|
Articaine vs. lidocaine. | 2007 Apr |
|
The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. | 2007 Apr |
|
Comparison of 4% articaine with 1:100,000 epinephrine and 2% lidocaine with 1:100,000 epinephrine when used as a supplemental anesthetic. | 2007 Apr |
|
The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. | 2007 Aug |
|
Epinephrine concentration (1:100,000 or 1:200,000) does not affect the clinical efficacy of 4% articaine for lower third molar removal: a double-blind, randomized, crossover study. | 2007 Dec |
|
Is articaine the hypoallergenic anesthetic? | 2007 Feb |
|
Hemostatic and anesthetic efficacy of 4% articaine HCl with 1:200,000 epinephrine and 4% articaine HCl with 1:100,000 epinephrine when administered intraorally for periodontal surgery. | 2007 Feb |
|
Articaine versus lidocaine: the author responds. | 2007 Jun |
|
[The influence of different local anaesthetics on the viability of preadipocytes]. | 2007 Jun |
|
Comparative study of the anesthetic efficacy of 4% articaine versus 2% lidocaine in inferior alveolar nerve block during surgical extraction of impacted lower third molars. | 2007 Mar 1 |
|
Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndrome. | 2007 May-Jun |
|
More about articaine. | 2007 Nov |
|
Efficacy of articaine. | 2007 Nov |
|
Effects of articaine on action potential characteristics and the underlying ion currents in canine ventricular myocytes. | 2007 Nov |
|
Articaine: a new alternative in dental hygiene pain control. | 2007 Summer |
|
A prospective, randomized, double-blind comparison of articaine and lidocaine for maxillary infiltrations. | 2008 Apr |
|
Comparison of 4% articaine and 0.5% levobupivacaine/2% lidocaine mixture for sub-Tenon's anaesthesia in phacoemulsification cataract surgery: a randomised controlled trial. | 2008 Apr |
|
Articaine interaction with DSPC bilayer: a 13C and 31P solid-state NMR study. | 2008 Apr 23 |
|
[Feasibility of permanent maxillary tooth removal using articaine anesthesia without palatal injection]. | 2008 Aug |
|
Efficacy of intraosseous injections of anesthetic in children and adolescents. | 2008 Aug |
|
Regional anesthesia techniques for ambulatory orthopedic surgery. | 2008 Dec |
|
Comparison of hyperbaric and plain articaine in spinal anaesthesia for open inguinal hernia repair. | 2008 Dec |
|
New Portland cement-based materials for endodontics mixed with articaine solution: a study of cellular response. | 2008 Jan |
|
An evaluation of buccal infiltrations and inferior alveolar nerve blocks in pulpal anesthesia for mandibular first molars. | 2008 Jan |
|
Spinal anaesthesia with articaine 5% vs bupivacaine 0.5% for day-case lower limb surgery: a double-blind randomized clinical trial. | 2008 Jan |
|
Analysis of the antimicrobial activity of local anaesthetics used for dental analgesia. | 2008 Jan |
|
A comparison of the clinical anesthetic efficacy of 4% articaine and 0.5% bupivacaine (both with 1:200,000 epinephrine) for lower third molar removal. | 2008 Jul |
|
Influence of local anesthethics with adrenalina 1:100.000 in basic vital constants during third molar surgery. | 2008 Jul 1 |
|
A comparison of injection pain with articaine with adrenaline, prilocaine with phenylpressin and lidocaine with adrenaline. | 2008 Jul 1 |
|
Anesthetic efficacy of the Gow-Gates injection and maxillary infiltration with articaine and lidocaine for irreversible pulpitis. | 2008 Jun |
|
The cardiovascular effect of local anesthesia with articaine plus 1:200,000 adrenalin versus lidocaine plus 1:100,000 adrenalin in medically compromised cardiac patients: a prospective, randomized, double blinded study. | 2008 Jun |
|
Hemodynamic changes during the surgical removal of lower third molars. | 2008 Mar |
|
Articaine hydrochloride: a safe alternative to lignocaine? | 2008 May |
|
Articaine infiltration for anesthesia of mandibular first molars. | 2008 May |
|
Articaine use in children among dental practitioners. | 2008 Nov-Dec |
|
Effects of low-intensity pulsed ultrasound on dental implant osseointegration: a preliminary report. | 2008 Oct |
|
Comparing anesthetic efficacy of articaine versus lidocaine as a supplemental buccal infiltration of the mandibular first molar after an inferior alveolar nerve block. | 2008 Sep |
|
A comparison of the anesthetic efficacy of articaine and lidocaine in patients with irreversible pulpitis. | 2009 Feb |
|
Plain articaine or prilocaine for spinal anaesthesia in day-case knee arthroscopy: a double-blind randomized trial. | 2009 Feb |
|
Comparison of anesthetic efficacy of 4% articaine and 2% lidocaine for maxillary buccal infiltration in patients with irreversible pulpitis. | 2009 Jan |
Sample Use Guides
For dental injection by submucosal infiltration or nerve block. For infiltration: 0.5-2.5 mL (20-100 mg articaine HCl). For nerve block: 0.5-3.4 mL (20-136 mg articaine HCl). For oral surgery: 1.0-5.1 mL (40-204 mg articaine HCl). Maximum recommended dosages: Adults: 7 mg/kg (0.175 mL/kg); Children 4-16 years: 7 mg/kg (0.175 mL/kg), depending on the age, weight and magnitude of the operation.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11421833
It was investigated the ability of local anaesthetics to inhibit reactive oxygen and nitrogen species generated by either stimulated human leucocytes or cell-free systems using luminol chemiluminescence (CL). Prilocaine inhibited formyl-methionyl-leucyl-phenylalanine (FMLP) - induced CL in leucocytes (94+/-1%, at 1 mM), whereas articaine showed an activation (59+/-7%) at high concentration (1 mM) and inhibition (13+/-6%) at low concentration (0.1 mM). In cell-free experiments, prilocaine (22+/-6%, at 1 mM) and articaine (85+/-1%, at 1 mM) caused concentration-dependent inhibition in xanthine-xanthine oxidase-induced CL. Although articaine had no effect on H2O2-induced CL, prilocaine significantly attenuated the H2O2 signal (97+/-0.3%, at 1 mM). Prilocaine (99+/-0.04%, 1 mM) and articaine (70+/-6%, 1 mM) markedly inhibited HOCl-induced CL, whereas these drugs had no effect on FeSO4-induced CL. Articaine inhibited peroxynitrite CL (63+/-6%, 1 mM), but prilocaine did not produce any depression on this signal.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QS9014Q792
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
245-957-7
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
100000089667
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
1042918
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
2117
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
m3139
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID2045444
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
23964-57-0
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
QS9014Q792
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
DB09009
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
C47404
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
SUB00597MIG
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
32169
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
OO-41
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1093
Created by
admin on Fri Dec 15 16:13:19 GMT 2023 , Edited by admin on Fri Dec 15 16:13:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD